Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations.
Open accessThe DOI matches its Crossref record; 128 of the 130 references it cites were found in a registry or an index.
Abstract
This paper discusses the current evidence from animal and human studies for a central role of inflammation in schizophrenia. In animal models, pre- or perinatal elicitation of the immune response may increase immune reactivity throughout life, and similar findings have been described in humans. Levels of pro-inflammatory markers, such as cytokines, have been found to be increased in the blood and cerebrospinal fluid of patients with schizophrenia. Numerous epidemiological and clinical studies have provided evidence that various infectious agents are risk factors for schizophrenia and other psychoses. For example, a large-scale epidemiological study performed in Denmark clearly showed that severe infections and autoimmune disorders are such risk factors. The vulnerability-stress-inflammation model may help to explain the role of inflammation in schizophrenia because stress can increase pro-inflammatory cytokines and may even contribute to a chronic pro-inflammatory state. Schizophrenia is characterized by risk genes that promote inflammation and by environmental stress factors and alterations of the immune system. Typical alterations of dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission described in schizophrenia have also been found in low-level neuroinflammation and consequently may be key factors in the generation of schizophrenia symptoms. Further support for the relevance of a low-level neuroinflammatory process in schizophrenia is provided by the loss of central nervous system volume and microglial activation demonstrated in neuroimaging studies. Last but not least, the benefit of anti-inflammatory medications found in some studies and the intrinsic anti-inflammatory and immunomodulatory effects of antipsychotics provide further support for the role of inflammation in this debilitating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence of altered inflammation-related markers across psychiatric conditions [6–8], along with reports of anti-inflammatory effects from psychotropic medications [9, 10] and the ameliorative impact of anti-inflammatory drugs on psychiatric symptoms [11–14], suggests a strong link between abnormal inflammatory responses and major psychiatric disorders.”
From Inflammatory ratios as predictors of length of hospitalization in psychiatric patients: A multicenter study (2025) · doi:10.1007/s00406-025-02033-9 · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A growing body of evidence suggests that immune dysfunction and inflammation have been considered to play important roles in the pathogenesis of SCZ and BD (11, 12).”
From Investigation of systemic immune-inflammation index, neutrophil/high-density lipoprotein ratio, lymphocyte/high-density lipoprotein ratio, and monocyte/high-density lipoprotein ratio as indicators of inflammation in patients with schizophrenia and bipolar disorder (2022) · cites this paper as [12]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Changes of some inflammation-related factors (IRFs) have been intensively studied and reviewed in relation to psychiatric disorders1–9.”
From Inflammation-related biomarkers in major psychiatric disorders: a cross-disorder assessment of reproducibility and specificity in 43 meta-analyses (2019) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Recent evidence suggests the involvement of the immune system in several psychiatric conditions [203–205]; one of the most studied in this respect is depression [206–208].”
From Molecular Characterisation of the Mechanism of Action of Stimulant Drugs Lisdexamfetamine and Methylphenidate on ADHD Neurobiology: A Review (2022) · cites this paper as [203]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murphy, K., & Weaver, C. (2016) · W.W. Norton eBooks · doi:10.1201/9781315533247 · Cited by 2,258
Vulnerability: A new view of schizophrenia.
Zubin, J., & Spring, B. (1977) · Journal of Abnormal Psychology · doi:10.1037/0021-843x.86.2.103 · Cited by 1,992
Cortical demyelination and diffuse white matter injury in multiple sclerosis
Kutzelnigg, A., Lucchinetti, C. F., Stadelmann, C., Brück, W., Rauschka, H., Bergmann, M., Schmidbauer, M., Parisi, J. E., & Lassmann, H. (2005) · Brain · doi:10.1093/brain/awh641 · Cited by 1,836
Goldsmith, D. R., Rapaport, M. H., & Miller, B. J. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.3 · Cited by 1,683
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
Maternal Immune Activation Alters Fetal Brain Development through Interleukin-6
Smith, S. E. P., Li, J., Garbett, K., Mirnics, K., & Patterson, P. H. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2178-07.2007 · Cited by 1,605
Serologic Evidence of Prenatal Influenza in the Etiology of Schizophrenia
Brown, A. S., Begg, M. D., Gravenstein, S., Schaefer, C. A., Wyatt, R. J., Bresnahan, M., Babulas, V. P., & Susser, E. S. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.8.774 · Cited by 1,053
The current status of the dopamine hypothesis of schizophrenia
CARLSSON, A. (1988) · Neuropsychopharmacology · doi:10.1016/0893-133x(88)90012-7 · Cited by 958
Neuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948
Cytokine-induced sickness behavior: where do we stand?
Dantzer, R. (2001) · Brain, Behavior, and Immunity · doi:10.1006/brbi.2000.0613 · Cited by 862
Cited by
Items 201–300 of 648
TLR/mTOR inflammatory signaling pathway: novel insight for the treatment of schizophrenia
Lashgari, N., Roudsari, N. M., Shamsnia, H. S., Shayan, M., Momtaz, S., & Abdolghaffari, A. H. (2023) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0107 · Cited by 15
Cavaleri, D., De Pietra, A., Gazzola, M., Crocamo, C., Bartoli, F., & Carrà, G. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107134 · Cited by 15
“Among these, a central role for immune-inflammatory activation has been hypothesized (Müller, 2018; Khandaker et al., 2015; Kirkpatrick and Miller, 2013) based on the elevated levels of pro-inflammatory cytokines and antibodies observed at different stages of illness (Halstead et al., 2023; Misiak…”
BackgroundPsychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
Romero‐Ferreiro, V., Fernandez, L. G., Romero, C., la Fuente, M. D., Cerro, E. D., Scala, M., González-Soltero, R., Álvarez-Mon, M. Á., Peñuelas‐Calvo, I., & Rodríguez–Jiménez, R. (2025) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2025.01.050 · Cited by 16
Li, C., Shi, Z., Ji, J., Niu, G., & Liu, Z. (2021) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s322005 · Cited by 16
Fendrich, S. J., Koralnik, L. R., Bonner, M., Goetz, D. M., Joe, P., Lee, J. J., Mueller, B. R., Robinson‐Papp, J., Gonen, O., Clemente, J. C., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114526 · Cited by 18
Kelley, D. P., Singleton, S. P., Venable, K. E., Sturm, G., Skovgaard, A., Francis, J., Neylan, T. C., Bradley, E., Woolley, J. D., Picard, M. A., et al. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106419 · Cited by 14
“Importantly, psychopathology is associated with chronic inflammation (Mellon et al., 2018; Miller and Raison, 2016; Müller, 2018; O’Donovan et al., 2017), which is metabolically expensive, contributing to systemic metabolic load (Bird, 2019; Ganeshan et al., 2019) during stress.”
InfluentialOxidative Stress-Mediated Neuroinflammation in the Pathophysiology of Schizophrenia
Trubalski, M., Markiewicz-Gospodarek, A., Żerebiec, M., Poleszak, J., Szczotka, M., Markiewicz, R., Łoza, B., & Szymańczyk, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262211139 · Cited by 18
Lee, H., Lee, Y., Chung, C., Park, S., Shin, H. J., Joe, E.-H., Lee, S. J., Kim, D. W., Jo, S., & Choi, S. (2024) · Glia · doi:10.1002/glia.24629 · Cited by 15
“…Kahn et al., 2015; van Os & Kapur, 2009), a psychiatric disorder with hallucination (i.e., positive symptom), abnormal thinking, and avolition (i.e., negative symptom) (Fillman et al., 2013; Fond et al., 2020; Goldsmith & Rapaport, 2020; Muller, 2018; Reus et al., 2015; Vidal & Pacheco, 2020).”
Tsai, S., Sajatovic, M., Hsu, J., Chung, K., Chen, P., & Huang, Y. (2020) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5291 · Cited by 16
“Mounting evidence obtained through MRI suggests that inflammatory processes are associated with anomalies in the brains of individuals with schizophrenia(11) and levels of pro-inflammatory markers, such as cytokines and the soluble cytokine receptor are elevated in the blood and cerebrospinal fluid of patients with sc…”
BackgroundStassen, H. H., Bachmann, S., Bridler, R., Cattapan, K., Herzig, D., Schneeberger, A. R., & Seifritz, E. (2020) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-020-01169-0 · Cited by 16
Izumi, R., Hino, M., Wada, A., Nagaoka, A., Kawamura, T., Mori, T., Sainouchi, M., Kakita, A., Kasai, K., Kunii, Y., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.653821 · Cited by 16
Joe, P., Clemente, J. C., Piras, E., Wallach, D. S., Robinson‐Papp, J., Boka, E., Remsen, B., Bonner, M., Kimhy, D., Goetz, D. M., et al. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.09.019 · Cited by 15
Kaya, Ş., Taşçı, G., Kılıç, N., Karadayı, H., Özsoy, F., & Atmaca, M. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030475 · Cited by 14
Social isolation produces a sex‐ and brain region‐specific alteration of microglia state
Vu, A. P., Lam, D., Denney, C., Lee, K. V., Plemel, J. R., & Jackson, J. (2023) · European Journal of Neuroscience · doi:10.1111/ejn.15966 · Cited by 17
“Chronic stress can lead to inflammatory processes in the brain which can also lead to the development of psychiatric disorders such as depression, anxiety and schizophrenia (Müller, 2018; Rooney et al., 2020; Wang et al., 2018).”
BackgroundZheng, C., Liu, H., Tu, W., Lin, L., & Xu, H. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231200257 · Cited by 13
Yu, H., Li, R., Liang, X., Yang, W., Guo, L., Liu, L., Tan, Q., & Peng, Z. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06277-y · Cited by 15
Savareh, E., Davoodian, N., Mousaviyan, R., Ghasemi‐Kasman, M., Atashabparvar, A., & Eftekhar, E. (2022) · Basic and Clinical Neuroscience Journal · doi:10.32598/bcn.2021.3361.1 · Cited by 14
“Several human studies have provided evidence that the etiology of schizophrenia involves neuroinflammation, abnormal morphology, and functionality of glial cells (Fillman et al., 2013; Müller, 2018; Potvin et al., 2008).”
BackgroundEffect of quetiapine on inflammation and immunity: a systematic review
Ferrari, M., Godio, M., Martini, S., Callegari, C., Cosentino, M., & Marino, F. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2101928 · Cited by 16
“Interestingly, an impaired immune response is linked to a number of brain disorders (Berger et al., 2009; Cao & Zheng, 2018; Muller, 2018), thus, it is conceivable that QUE immunomodulatory effects could even contribute to the antipsychotic”
BackgroundNeuroinflammation in Bilirubin Neurotoxicity
Zhang, F., Chen, L., & Jiang, K. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2201009 · Cited by 16
Influence of Cyclooxygenase-2 Inhibitors on Kynurenic Acid Production in Rat Brain in Vitro
Zakrocka, I. N., Targowska‐Duda, K. M., Wnorowski, A., Kocki, T., Jóźwiak, K., & Turski, W. A. (2018) · Neurotoxicity Research · doi:10.1007/s12640-018-9952-9 · Cited by 13
“Abbreviations COX-2, cyclooxygenase-2; CRP, C-reactive protein; DA, dopamine; DFU, (5,5-dimethyl-3-(3-fluorophenyl)-4-(4methylsulphonyl) phenyl-2((5)H)-furanone); DMSO, dimethyl sulfoxide; GLU, glutamate; HPLC, high-performance liquid chromatography; IDO, indoleamine 2,3-dioxygenase; IL-1β, interleukin-1 beta; IL-2, i…”
BackgroundInfluentialFortuna, K. L., Williams, A., Mois, G., Jason, K., & Bianco, C. L. (2021) · Perspectives on Psychological Science · doi:10.1177/1745691621990613 · Cited by 13
“Chronic stress in SMI can desensitize the immuneinflammation response, allowing for less stressful stimuli needed to activate said response (Muller, 2018).”
BackgroundCandidates for Drug Repurposing to Address the Cognitive Symptoms in Schizophrenia
Koch, E. M., Kauppi, K., & Chen, C. (2022) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2022.110637 · Cited by 14
Role of de novo lipogenesis in inflammation and insulin resistance in Alzheimer's disease
Khan, M. A., Khan, Z. A., Shoeb, F., Fatima, G., Khan, R. H., & Khan, M. M. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.124859 · Cited by 14
Schizophrenia and the COVID-19 pandemic: A narrative review from the biomedical perspective
Kowalski, K., & Misiak, B. (2023) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2023.04.002 · Cited by 16
Leung, K. K., Wong, Y. C., Shea, K. S. C., Chan, S. C., Chang, W. C., Mo, Y. M. F., & Chan, S. S. M. (2023) · Scientific Reports · doi:10.1038/s41598-023-37846-y · Cited by 18
Metabolic Syndrome Causing Cognitive Impairment in Patients With Schizophrenia: A Systematic Review
Saxena, A., Patel, D. N., Ayesha, I. E., Monson, N. R., Klair, N., Patel, U. P., & Khan, S. (2023) · Cureus · doi:10.7759/cureus.47587 · Cited by 18
“These changes further lead to microglial activation in the brain as these are the immune cells of the brain, which ultimately leads to brain structure remodeling and subsequently may lead to cognitive impairment [15,18,19].”
BackgroundSun, X., Luo, G., Li, X., Wang, J., Qiu, Y., Li, M., & Li, J. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01677-9 · Cited by 13
“It is mainly involved in the activation and aggregation of microglia, cytokine expression imbalance, and astrocyte changes [6].”
Zheng, Y., Zhang, Q., Zhou, X., Yao, L., Zhu, Q., & Fu, Z. (2023) · Scientific Reports · doi:10.1038/s41598-023-49206-x · Cited by 13
“…been many similar studies that sought to explore the relationship between immune function and schizophrenia through peripheral immune markers 25–27 , and much evidence confirms that dysregulation of immune system has a significant impact on onset and progression of schizophrenia or other…”
BackgroundJi, X., Chai, J., Zhao, S., & Zhao, Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1605027 · Cited by 16
“When the brain encounters injury, local in fl ammation, or responds to systemic in fl ammation, microglial cells are activated, exhibiting speci fi c changes such as morphological alterations, enhanced expression of surface markers, promotion of T-cell activity, and secretion of various in fl ammatory factors (Dantzer, 20…”
AUTOIMMUNE CONCEPT OF SCHIZOPHRENIA: HISTORICAL ROOTS AND CURRENT FACETS
Mayorova, M. A., Георгиевич, Б. Б., Churilov, L. P., Gilburd, B., Petrova, N. N., & Shoenfeld, Y. (2021) · Psychiatria Danubina · doi:10.24869/psyd.2021.3 · Cited by 16
Ma, J., Zhang, Y., Huang, Z., Liu, X., Lv, L., & Li, Y. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.782289 · Cited by 13
Immunologic profiling in schizophrenia and rheumatoid arthritis
Eaton, W. W., Rodriguez, K. M., Thomas, M. A., Johnson, J. H., Talor, M. V., Dohan, C. F., Bingham, C. O., Musci, R. J., Roth, K. B., Kelly, D. L., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114812 · Cited by 12
Guimarães, A. L., Coelho, D. R. A., Scoriels, L., Mambrini, J. V. D. M., Antonelli, L. R. D. V., Henriques, P. M., Teixeira‐Carvalho, A., Martins‐Filho, O. A., Mineo, J. R., Bahia‐Oliveira, L. M. G., et al. (2022) · Schizophrenia · doi:10.1038/s41537-022-00292-2 · Cited by 13
Chen, S., Chen, G., Li, Y., Yue, Y., Zhu, Z., Li, L., Jiang, W., Shen, Z., Wang, T., Hou, Z., et al. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-022-01540-3 · Cited by 16
“Moreover, these three hypotheses are also related to the pathophysiology of SZ [16–19], BPD [20–22], and PD [23–25].”
BackgroundUranova, N. A., Vikhreva, O. V., & Рахманова, В. И. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01621-x · Cited by 12
“Prolonged microglial activation may cause neuronal degeneration by producing various pro-inflammatory cytokines and free radicals [38, 39].”
BackgroundCortisol and cytokines in schizophrenia: A scoping review
Farcas, A., Christi, P., & Iftene, F. (2023) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2023.100192 · Cited by 14
“Among the myriad of factors discussed in the literature, inflammation stands out as an important factor in schizophrenia pathophysiology [5].”
BackgroundMinocycline as a treatment for schizophrenia: is the discussion truly finished?
Kishimoto, T., Horigome, T., & Takamiya, A. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30389-4 · Cited by 12
nflammation and damage-associated molecular patterns in major psychiatric disorders
Valiati, F. E., Feiten, J. G., Géa, L. P., Júnior, É. D. M. S., Scotton, E., Caldieraro, M. A., Salum, G. A., & Kauer‐Sant’Anna, M. (2023) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089-2022-0576 · Cited by 19
“32,33 It .”
The Immunoseasonal Theory of Psychiatric Disorders
Waszkiewicz, N. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144615 · Cited by 14
Santo, F. D., González-Blanco, L., García‐Portilla, M. P., Alfonso, M., Hernández, C., Sánchez-Autet, M., Bernardo, M., Anmella, G., Amoretti, S., Safont, G., et al. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.10.004 · Cited by 12
“Multiple theories have been suggested, and these can be integrated into the framework of a vulnerability-stress-inflammation model (Müller, 2018).”
Leveraging the Metaverse for Enhanced Longevity as a Component of Health 4.0
Pillay, S. S., Candela, P., Croghan, I. T., Hurt, R. T., Bonnes, S. L. R., Ganesh, R., & Bauer, B. A. (2024) · Mayo Clinic Proceedings Digital Health · doi:10.1016/j.mcpdig.2024.01.007 · Cited by 13
Hoprekstad, G. E., Skrede, S., Bartz-Johannessen, C. A., Joa, I., Reitan, S. K., Steen, V. M., Torsvik, A., Johnsen, E., Kroken, R. A., & Rettenbacher, M. A. (2024) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2024.100756 · Cited by 17
“Associations between psychosis and inflammation are well established (Raison et al., 2006; Muller, 2018; Rengasamy et al., 2020; Haroon et al., 2020; Sha et al., 2022).”
BackgroundNorth, H. F., Weissleder, C., Bitar, M., Barry, G., Fullerton, J. M., Webster, M. J., & Weickert, C. S. (2024) · Schizophrenia · doi:10.1038/s41537-024-00466-0 · Cited by 15
Relationship of metabolites and metabolic ratios with schizophrenia: a mendelian randomization study
Huang, Y., Wang, H.-X., Zheng, J., & Zhou, N. (2024) · Annals of General Psychiatry · doi:10.1186/s12991-024-00521-1 · Cited by 12
“The vul-nerability-stress-inflammation model for schizophrenia currently suggests that neuroinflammation is one of the potential causes of schizophrenia [40].”
BackgroundMitochondrial Dysfunction and Cognitive Impairment in Schizophrenia: The Role of Inflammation
Wang, G., Liu, S., Fan, X., Li, J., Xue, Q., Liu, K., Li, X., Yang, Y., Wang, X., Song, M., et al. (2024) · Schizophrenia Bulletin · doi:10.1093/schbul/sbae196 · Cited by 17
IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
Moran, P. M., & Granger, K. T. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107727 · Cited by 13
George, M. Y., Farag, N., Menze, E. T., Elezaby, R. S., Salem, N. A., Elrahmany, S. K., Adel, N., ElKhatib, R. M., Galal, M., Assem, H., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-00918-2 · Cited by 13
Nicholson, K., MacLusky, N. J., & Leranth, C. (2020) · Vitamins and hormones · doi:10.1016/bs.vh.2020.06.002 · Cited by 13
Santo, F. D., González-Blanco, L., García-Álvarez, L., de la Fuente-Tomás, L., Velasco, Á., Alvarez-Vázquez, C., Martínez-Cao, C., Sáiz, P. A., García‐Portilla, M. P., & Bobes, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-73043-x · Cited by 11
Susai, S. R., Mongan, D., Healy, C., Cannon, M. D., Nelson, B., Markulev, C., Schäfer, M. R., Berger, M., Mossaheb, N., Schlögelhofer, M., et al. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.09.018 · Cited by 12
“…in neurons) have been noticed from an early stage of psychosis, intervening at an earlier phase with omega-3 FA has been suggested as an option for preventing or delaying the development of psychosis (Muller et al., 2015; Müller, 2018; Hsu et al., 2020; Mongan et al., 2020; Mongan et al., 2021).”
BackgroundInfluentialCannabis Cessation, Inflammatory Markers and Schizophrenia
Roméo, B., Lestra, V., Martelli, C., Benyamina, A., & Hamdani, N. (2022) · Journal of Dual Diagnosis · doi:10.1080/15504263.2021.2013697 · Cited by 12
Guan, X., Xu, J., Xiu, M., Li, X., Liu, H., & Wu, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13895 · Cited by 10
Sabaie, H., Gholipour, M., Asadi, M. R., Abed, S., Sharifi‐Bonab, M., Taheri, M. N., Hussen, B. M., Brand, S., Neishabouri, S. M., & Rezazadeh, M. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1010977 · Cited by 12
Wang, Y., Fang, X., Wang, G., Tang, W., Liu, S., Yang, Y., Chen, J., Ling, Y., Zhou, C., Zhang, X., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.06.016 · Cited by 14
Szabó, A., Akkouh, I. A., Ueland, T., Lagerberg, T. V., Dieset, I., Bjella, T. D., Aukrust, P., Hellard, S. L., Stavrum, A.-K., Melle, I. S., et al. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00642 · Cited by 9
“…of SCZ, dysregulated and/or low-grade chronic brain inflammation may interfere with cognition, mood regulation, and higher-order functioning, and any means of modulating this “inflammatory immune-brain” cross-talk may pose a potential therapeutic target (Khandaker et al., 2015; Müller, 2018).”
BackgroundHata, M., Fujimoto, M., Kanai, K., Yoshiyama, K., Nakatani, Y., Nakabayashi, D., Maemura, S., Kawata, S., Hakozaki, T., Nishikura, S., et al. (2021) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12166 · Cited by 10
Higher Dietary Inflammation in Patients with Schizophrenia: A Case-Control Study in Korea
Yun, H. S., Yang, S. J., & Kim, S. (2021) · Nutrients · doi:10.3390/nu13062033 · Cited by 12
“Inflammation has been suggested as a potential etiological factor in schizophrenia [41,42].”
BackgroundHansen, N., & Malchow, B. (2023) · Psychiatria Danubina · doi:10.24869/psyd.2023.8 · Cited by 11
González‐Castro, T. B., Tovilla‐Zárate, C. A., Juárez‐Rojop, I. E., Hernández‐Díaz, Y., López‐Narváez, M. L., & Ojeda, R. F. O. (2023) · Brain Research · doi:10.1016/j.brainres.2023.148667 · Cited by 11
Chen, L., Zheng, C., Luan, H., & Chen, X. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s473528 · Cited by 10
“1,2 Recent studies indicate that inflammation and immune dysfunction, both within the central nervous system and peripheral immune responses, 3,4 along with oxidative stress, play significant roles in the pathophysiology of SCZ.”
BackgroundHuang, Z., Chen, G., Ren, Z., Xiao, L., Chen, Z., Xie, Y., Wang, G., & Zhou, B. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114336 · Cited by 11
IUPHAR review – Novel therapeutic targets for schizophrenia treatment: A translational perspective
Begni, V., Marchesin, A., & Riva, M. A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107690 · Cited by 14
The roles of immune factors in neurodevelopment
Wang, C., He, T., Qin, J., Jiao, J., & Ji, F. (2025) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2025.1451889 · Cited by 20
“While the precise etiology of schizophrenia remains elusive, growing evidence suggests that the disorder is significantly influenced by interactions between the immune and nervous systems, akin to other neurodevelopmental disorders (Müller, 2018).”
Allimuthu, P., Nandeesha, H., Chinniyappan, R., Bhardwaz, B., & Jesudas, B. R. (2020) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-020-00880-y · Cited by 8
Turner, A., Baker, A., Dean, O. M., Walker, A. J., Dodd, S., Cotton, S., Scott, J. G., Kavanagh, B. E., Ashton, M. M., Brown, E., et al. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720982437 · Cited by 14
Progress in mechanistically novel treatments for schizophrenia
Neef, J., & Palacios, D. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00096a · Cited by 10
Can the current schizophrenia construct endure?
Kelly, D. L., & Buchanan, R. W. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2021.12.028 · Cited by 10
Recent advancements in biomarker research in schizophrenia: mapping the road from bench to bedside
Patel, S., Sharma, D., Uniyal, A., Akhilesh, A., Gadepalli, A., & Tiwari, V. K. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-022-00926-5 · Cited by 11
“Therefore, IL-2 levels could serve as a theranostic SZ-specific biomarker as its levels fall when antipsychotic treatment is started and might reflect the true cognitive function and clinical symptoms of patients (Müller 2018).”
BackgroundInfluentialKlyushnik, T. P., Ab, S., Голимбет, В. Е., Zozulya, S. A., & Voronova, E. I. (2022) · Psikhiatriya · doi:10.30629/2618-6667-2022-20-2-6-13 · Cited by 10
Liu, L., Wu, Q., Li, X., Song, R., Wei, N., Liu, J., Yuan, J., Yan, S., Sun, X., Liang, Y., et al. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.162057 · Cited by 11
Lokmer, A., Goud, A. C., Troudet, R., Bacq‐Daian, D., Boland, A., Latapie, V., Deleuze, J., Rajkumar, R. P., Shewade, D. G., Bélivier, F., et al. (2023) · Epigenomics · doi:10.2217/epi-2023-0017 · Cited by 15
Yan, F., Meng, X., Cheng, X., Pei, W., Chen, Y., Chen, L., Zheng, M., Shi, L., Zhu, C., & Zhang, X. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04913-7 · Cited by 16
“Previous studies have identified SCZ as a neurodevelopmental disorder caused by proinflammatory risk genes, environmental stress factors, and immune system alterations [4, 5].”
BackgroundRaghava, J. M., Mandl, R. C. W., Nielsen, M. Ø., Fagerlund, B., Glenthoj, B. Y., Rostrup, E., & Ebdrup, B. H. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-019-00230-4 · Cited by 9
Gebicke‐Haerter, P. J., Leonardi‐Essmann, F., Haerter, J. O., Rossner, M. J., Falkai, P., Schmitt, A., & Raabe, F. J. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2021.04.014 · Cited by 8
Rebouças, D. B., Rabelo‐da‐Ponte, F. D., Massuda, R., Czepielewski, L. S., & Gama, C. S. (2018) · NeuroImmunoModulation · doi:10.1159/000492716 · Cited by 11
Jankowska, A., Satała, G., Partyka, A., Wesołowska, A., Bojarski, A. J., Pawłowski, M., & Chłoń‐Rzepa, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190710172002 · Cited by 11
Neuroimmune, clinical and treatment challenges in multiple sclerosis-related psychoses
Vesić, K., Gavrilović, A., Mijailović, N. R., & Borovčanin, M. (2023) · World Journal of Psychiatry · doi:10.5498/wjp.v13.i4.161 · Cited by 9
Serpa, M. H., Doshi, J. J., Joaquim, H. P. G., Vieira, É. L. M., Erus, G., Chaim-Avancini, T. M., Cavallet, M., Guglielmi, L. G., Sallet, P. C., Talib, L. L., et al. (2023) · Schizophrenia Research · doi:10.1016/j.schres.2023.05.005 · Cited by 11
Bulduk, B. K., Tortajada, J., Valiente-Pallejà, A., Callado, L. F., Torrell-Galceran, H., Vilella, E., Meana, J. J., Muntané, G., & Martorell, L. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115928 · Cited by 9
“Systemic abnormalities associated with SZ, such as inflammation (Müller, 2018), redox dysregulation (Kim et al., 2017), and oxidative stress (Jiang et al., 2019), involve mitochondria, and several lines of evidence suggest that mitochondrial abnormalities may contribute to impaired brain function…”
BackgroundLysosome-Targeted Si-rhodamine Derivative for NO Imaging in Mice Brain with Neurological Diseases
Wang, K., Zhou, J., Geng, Y., Zhang, G., Zhang, Z., Jin, Y., Liu, X., & Wang, Z. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c01448 · Cited by 9
Hong, F., Chen, Q., Luo, X., Xie, S., Wei, Y., Li, X., Li, K., Lebeau, B., Ling, C. C. Y., Dao, F., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157640 · Cited by 11
No alteration of leukocyte telomere length in first episode psychosis
Schürhoff, F., Corfdir, C., Pignon, B., Lajnef, M., Richard, J., Marcos, É., Pélissolo, A., Leboyer, M., Adnot, S., Jamain, S., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113941 · Cited by 11
Anti-Inflammatory Therapy as a Promising Target in Neuropsychiatric Disorders
Ballaz, S., & Bourin, M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_20 · Cited by 17
Liu, S., Zhang, X., Wang, J., Yang, H., Jiang, Y., Qiu, C., & Meng, Q. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577165 · Cited by 9
Chen, P., Tsai, S., Pan, C., Chang, H., Chen, Y., Su, S., Chen, C., & Kuo, C. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720948429 · Cited by 9
Kaur, K. K., Allahbadia, G. N., & Singh, M. (2020) · Obesity Research - Open Journal · doi:10.17140/oroj-7-143 · Cited by 15
Thomas, N., Gurvich, C., Hudaib, A., Gavrilidis, E., Castella, R. A. D., Thomas, E. H. X., & Kulkarni, J. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105165 · Cited by 10
Accelerated aging signatures in subjects with schizophrenia and their unaffected siblings
Rebouças, D. B., Sartori, J., Librenza‐Garcia, D., Rabelo‐da‐Ponte, F. D., Massuda, R., Czepielewski, L. S., Passos, I. C., & Gama, C. S. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.04.029 · Cited by 10
Susai, S. R., Mongan, D., Healy, C., Cannon, M. D., Cagney, G., Wynne, K. J., Byrne, J. F., Markulev, C., Schäfer, M. R., Berger, M., et al. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.03.013 · Cited by 10
Recurrence network analysis of schizophrenia MEG under different stimulation states
Bai, D., Yao, W., Wang, S., Yan, W., & Wang, J. (2022) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2022.104310 · Cited by 9
Roméo, B., Lestra, V., Martelli, C., Amirouche, A., Benyamina, A., & Hamdani, N. (2023) · Acta Neuropsychiatrica · doi:10.1017/neu.2023.24 · Cited by 11
“The vulnerability-stress-inflammation model (Howes & McCutcheon, 2017; Müller, 2018; Lestra et al ., 2022) implies an imbalance of the microglia activation (M1/M2 pathways ’ homeostasis) leading to an over-expression of pro-inflammatory cytokines (Howes & McCutcheon, 2017).”
BackgroundDietary inflammatory index and neuropsychiatric disorders
Nasab, M. G., Heidari, A., Sedighi, M., Shakerian, N., Mirbeyk, M., Saghazadeh, A., & Rezaei, N. (2023) · Reviews in the Neurosciences · doi:10.1515/revneuro-2023-0047 · Cited by 9
Li, L., Du, F., Liu, X., Song, M., Grosso, G., Battino, M., Boesch, C., Li, H., & Liu, X. (2025) · Foods · doi:10.3390/foods14101773 · Cited by 8
“Low-level inflammation exacerbates the symptoms of SZ through dopaminergic, serotonergic, noradrenergic, and glutamatergic neurotransmission [51].”
Cell adhesion molecules in the pathogenesis of the schizophrenia
Messina, A., Crescimanno, C., Cuccì, G., Caraci, F., & Signorelli, M. S. (2023) · Folia Medica · doi:10.3897/folmed.65.e101356 · Cited by 9
Duan, L., Li, S., Chen, D., Shi, Y., Zhou, X., & Feng, Y. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-06287-w · Cited by 11
“Prior studies have revealed a connection between neuroinflammation, autoimmunity, and SCZ [5–8].”
Romero‐Ferreiro, V., Fernandez, L. G., Fernández, J. M. B., Romero, C., González-Soltero, R., la Fuente, M. D., Álvarez-Mon, M. Á., Wynn, R., & Rodríguez–Jiménez, R. (2025) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2025.103126 · Cited by 11
Evaluation of Inflammatory Markers in Perception Disorders in Major Psychiatric Pathology
Segarceanu, L.-M., Zanfir, A.-G., Mincă, D. G., & Trifu, S. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199299 · Cited by 12
Yang, Y., Li, M., Liu, Y., Luo, B., Ge, M., Zhang, K., liu, H., & He, H. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178272 · Cited by 8
Gibbons, A. S., Hoyer, D., & Dean, B. (2020) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1733081 · Cited by 8
“Disruption of inflammatory processes is now widely recognised as part of the pathophysiology of schizophrenia (Muller 2018; Pouget 2018; Mongan et al. 2019).”
Background
Metadata
- Authors
- Müller, N.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Corresponding author
- Müller, Norbert
- ORCID
- Müller, Norbert
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-04-10
- Volume
- 44
- Issue
- 5
- Pages
- 973-982
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC6101562
- OpenAlex
- W2888647009
- Cited by
- 648
- References
- 130
- Citations by year
- 2026: 62 · 2025: 88 · 2024: 92 · 2023: 116 · 2022: 102 · 2021: 98 · 2020: 62 · 2019: 18 · 2018: 9
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model (vor)
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- schizophrenia, neuroinflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Humans, Inflammation, Schizophrenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.